Organon Pharma Indonesia Tbk. vs Perintis Triniti Properti Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Perintis Triniti Properti Tbk. trades at Rp414 (market cap 1.87T, 31.81M 24h volume). The key difference: Perintis Triniti Properti Tbk. is far larger — about 17.9× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | TRIN | |
|---|---|---|
Market Cap | 104.4B | 1.87T |
Volume | — | 31.81M |
Lot | — | 318.13K |
Turnover | — | 12.84B |
Average Price | — | 403.61 |
Value | — | 12.84B |
Indicative Equilibrium Price | — | 414 |
Indicative Equilibrium Volume | — | 6.57K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →PT Perintis Triniti Properti Tbk (the Company) was established dated March 13, 2009 based on Notarial Deed No. 06 of Drs. Arif Djohan Tunggal, S.H., M.H., M.Kn., Notary in Jakarta.
Read more on TRIN →